MUMBAI, India, April 10 -- Intellectual Property India has published a patent application (202411073234 A) filed by Indian Council Of Agricultural Research, New Delhi, on Sept. 27, 2024, for 'ma-104 cell adapted live attenuated african swine fever virus as a vaccine candidate.'
Inventor(s) include Senthil Kumar D.; K. Rajukumar; G. Venkatesh; Fateh Singh; Gopal Sarkar; and Aniket Sanyal.
The application for the patent was published on April 10, under issue no. 15/2026.
According to the abstract released by the Intellectual Property India: "MA-104 cell adapted live attenuated African Swine fever virus as a vaccine candidate The present invention relates to a modified live attenuated African swine fever virus (ASFV) for use as a vaccine. This invention specifically pertains to an ASFV strain that has been attenuated through adaptation and serial passaging of a field strain in the MA-104 cell line, which is derived from monkey kidney cells. The ASFV field strain, originally isolated from a porcine serum sample collected in Punjab in 2022, underwent serial passages in the MA-104 cell line up to 95 passages (ASFV-P95). The present invention also relates to the use of MA-104 cell adapted live attenuated African Swine fever virus as a vaccine candidate (ASFV P95) to treat and/or prevent African swine fever. When administered intramuscularly at a dose of 10 to 105 HAD50 of ASFV-P95 which is fully attenuated, the vaccinated domestic pigs are completely asymptomatic. Administration of the attenuated ASFV-P95 conferred protective immunity in five out of six immunized domestic pigs when challenged with the virulent parental ASFV strain at 35 days post-immunization."
Disclaimer: Curated by HT Syndication.
